Enliven Therapeutics Q2 net loss widens on higher expenses

Enliven Therapeutics

05/08/2026 21:18

Overview
US biopharmaceutical firm's Q2 net loss widened yr/yr as operating expenses increased
Company announced positive Phase 1 clinical data for ELVN-001 in CML
Cash position rose to $895 mln, expected to provide runway into 2030

Outlook
Enliven expects to initiate ENABLE-2 Phase 3 trial for ELVN-001 in H2 2026
Company expects cash runway to last into 2030
Additional Phase 3 trial design details to be finalized after planned FDA meeting in Q3 2026

Result Drivers
R&D INVESTMENT - Co said higher research and development expenses reflected advancement of ELVN-001 clinical program
CLINICAL DATA - Co announced positive Phase 1 clinical data for ELVN-001 in CML, supporting further development
REGULATORY PROGRESS - Co reached alignment with FDA on key Phase 3 trial design and received Fast Track designation

Company press release: ID:nPn3skxjXa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
 
$32.49 mln
 
Q2 Income From Operations
 
-$37.21 mln
 
Q2 Loss Per Basic Share
 
$0.49
 
Q2 Operating Expenses
 
$37.21 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Enliven Therapeutics, Inc. is $63.50, about 3.9% above its August 4 closing price of $61.11

Reuters Recommended Reads
Aug 4 - Tyra Biosciences Q2 net loss widens on higher R&D expenses
Aug 4 - Dianthus Therapeutics Q2 net loss widens as R&D costs rise
Aug 4 - Spyre Therapeutics Q2 loss narrower than expected; sees trial readouts in 2026

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)